ο

U of T’s Deep Genomics secures $40 million in financing for AI drug development platform: Betakit

portrait of Brendan Frey seated at a desk
Brendan Frey is the CEO of Deep Genomics and a professor in U of T's Faculty of Applied Science & Engineering (photo by Johnny Guatto)

Deep Genomics, an artificial intelligence-powered drug discovery start-up co-founded by the University of Toronto’s Brendan Frey, recently raised $40 million in Series B funding, .

The latest round, led by Future Ventures and including investments from Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures, brings the startup’s total funding to date to $61 million.

Betakit notes that Deep Genomics in September “identified a new treatment target and corresponding drug candidate for Wilson disease,” a rare genetic disorder that causes an accumulation of copper in vital organs, which can be fatal if left untreated.

The capital will help Deep Genomics, , bring its Wilson disease program to the clinic, said Frey, a founding member of the Vector Institute for Artificial Intelligence and a professor in the department of electrical and computer engineering in the Faculty of Applied Science & Engineering. 

UTC